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Abstract Endothelin-3 (ET-3), a potent vasoactive peptide, is
considered to be produced from big ET-3 by endothelin-
converting enzyme (ECE) like the other members of the
endothelin family (ET-1 and ET-2). We purified a novel ECE
from bovine iris microsomes. The purified enzyme, a 140 kDa
protein by SDS-PAGE analysis, converted big ET-3 to ET-3 but
not big ET-1, with a Km value of 0.14 WM for big ET-3. The
conversion to ET-3 was confirmed with sandwich EIA by
monoclonal antibodies, the elution profile of HPLC, and
intracellular calcium mobilization in CHO-K1 cells expressing
recombinant human ETB receptors. The conversion activity was
inhibited by an inhibitor of neutral endopeptidase 24.11 (NEP)
phosphoramidon. These results show that ECE-3 purified from
bovine iris is a novel metalloprotease totally different from ECE-
1 or ECE-2, in that the enzyme is highly specific for big ET-3.
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1. Introduction
Endothelin-1 (ET-1), originally isolated from the condi-
tioned medium of cultured porcine aortic endothelial cells, is
a potent vasoconstrictor with 21 amino acid residues [1]. The
endothelin family consists of three isopeptides: ET-1, ET-2
and ET-3 [2]. In the ¢rst step of biosynthesis of ET-1, a large
precursor designated preproET-1 is formed. After enzymatic
removal of a signal peptide [1,3,4], proET-1 is cleaved by a
furin-like protease which belongs to the calcium-dependent
serine endoproteases on the C-terminal side of the sequence
Arg-Ser-Lys-Arg, leading to formation of big ET-1 [5^8]. Big
ET-1 is ¢nally cleaved at the Trp21-Val22 bond to form mature
ET-1. This reaction is catalyzed by an enzyme called endothe-
lin-converting enzyme (ECE). On the other hand, the precise
biosynthetic pathway of ET-3 is not ¢rmly established but is
considered to be similar to that of ET-1, based on the follow-
ing observations. (1) The amino acid sequence of preproET-3
predicted from cloned cDNA has the consensus sequence Arg-
X-Lys/Arg-Arg [2] for furin-like enzymes. (2) The big ET-3-
like peptide has been identi¢ed immunologically in tissues that
produce mature ET-3 [9^11]. (3) ET-3 is produced by incubat-
ing big ET-3 with the membrane fraction from bovine endo-
thelial cells [12].
So far cDNAs for two types of ECE have been cloned from
rat lung and adrenal cortex, and designated ECE-1 [13^16]
and ECE-2 [17], respectively. The predicted amino acid se-
quence of ECE-1 is similar to that of ECE-2 with an overall
identity of 59% [17]. These enzymes are metalloproteases with
a zinc-binding motif [13^16]. The enzyme activities are inhib-
ited by phosphoramidon, an inhibitor of neutral endopepti-
dase 24.11 (NEP), but not thiorphan, another inhibitor of
NEP [18^20]. Both ECE-1 and ECE-2 show a high substrate
speci¢city for big ET-1 but not for big ET-2 and big ET-3,
although the optimal pHs are slightly di¡erent between these
two enzymes [17].
In several tissues like the eyeball and some brain regions,
the expression of preproET-3 determined by Northern analy-
sis and in situ hybridization was reported to be higher than
that of preproET-1 or preproET-2 [21^25], with the highest
level in the eyeballs. However, no enzyme speci¢c for big ET-3
has yet been puri¢ed. These results encouraged us to purify a
novel ECE speci¢c for big ET-3, namely, ECE-3. In this
study, we report the puri¢cation of ECE-3 from bovine iris
and some properties of the puri¢ed enzyme.
2. Materials and methods
2.1. Materials
Chemicals were purchased from the following sources: human ET-
1, ET-3, big ET-1 and big ET-3 from Peptide Institute Inc. (Osaka,
Japan); blue B-agarose from Millipore (Massachusetts, USA); peanut
agglutinin (PNA) agarose and wheat germ agglutinin (WGA) agarose
from Seikagaku Co. (Tokyo, Japan); a Hiload 26/60 Superdex 200 pg
column, a HiTrap Chelating column (1 ml), and a Resource Q column
(1 ml) from Amersham Pharmacia Biotech (Uppsala, Sweden); and a
Cosmosil 5C18-AR reverse phase column (4.6 mmU250 mm) from
Nacalai Tesque (Kyoto, Japan), fura-2 acetoxymethyl ester (fura-2/
AM) from Dojindo Laboratories (Kumamoto, Japan).
2.2. Solubilization of the bovine iris microsome
Fresh bovine eyeballs were obtained from a local slaughterhouse.
Irises were isolated from the surrounding tissues and stored until use
in phosphate-bu¡ered saline (PBS) at 380‡C. Irises from 200 eyeballs
were homogenized in 100 ml of PBS using a Polytron homogenizer at
4‡C. All subsequent procedures were carried out at 4‡C unless other-
wise stated. The homogenates were centrifuged at 1100Ug for 15 min,
and the resulting supernatant was centrifuged at 140 000Ug for 20
min. For washing, the precipitated microsomes were resuspended in
100 ml of PBS using an ultrasonic disruptor and centrifuged again.
This procedure was repeated once more and ¢nally the pellet was
resuspended in 100 ml of the solubilizing bu¡er (10 mM Tris-HCl,
pH 7.5, 0.1% lubrol PX). After gentle stirring for 60 min, the sample
was centrifuged at 140 000Ug for 20 min, and the resulting super-
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natant was used as a starting material for the subsequent puri¢cation
steps.
2.3. Puri¢cation of ECE-3
Solid sodium chloride was added to the solubilized supernatant to a
¢nal concentration of 200 mM. The supernatant was mixed with 10 ml
of blue B-agarose equilibrated with bu¡er A (10 mM Tris-HCl,
200 mM NaCl, 0.1% lubrol PX; pH 7.5) and the mixture was incu-
bated for 50 min. After the agarose had settled (V15 min), the clear
supernatant was ¢ltered through 0.2 Wm ¢lters of polystyrene, and
loaded onto six PNA agarose columns (0.8U4 cm) equilibrated with
bu¡er A. The £ow-through fractions were collected and applied onto
six WGA agarose columns (0.8U4 cm) equilibrated with bu¡er A.
After washing with 10 ml of bu¡er B (10 mM Tris-HCl, 1 M NaCl,
0.1% lubrol PX; pH 7.5), the enzyme activity was eluted with 5.5 ml
of bu¡er A containing 50 mg/ml N-acetyl-D-glucosamine. The eluate
was pooled and concentrated to a volume of approximately 2 ml with
a Centriprep-30 concentrator (Millipore). The concentrated eluate was
applied onto a Hiload 26/60 Superdex 200 pg column equilibrated
with bu¡er A, and gel ¢ltration was carried out using an Amersham
Pharmacia FPLC instrument (Controller LCC-500 Plus equipped with
Pump P-500). ECE activity was eluted with bu¡er A at a £ow rate of
1 ml/min and the absorbance of the out£ow was monitored at 280 nm.
Two-ml fractions were collected, and the activity in each fraction was
measured. The fractions with ECE-3 activity were pooled and solid
sodium chloride was added to them to a ¢nal concentration of 1 M.
The pooled fractions were applied onto a HiTrap Chelating column,
the matrix of which was charged with zinc ions using 0.1 M ZnSO4
and subsequently equilibrated with bu¡er B. The ECE activity was
recovered in the pass-through fraction.
2.4. Assay for ECE activity
The standard reaction mixture contained 50 Wl of puri¢ed ECE-3,
0.5 WM big ETs as a substrate, and 250 Wl of ECE reaction bu¡er (100
mM Tris-HCl, 2 WM ZnCl2, 1 M NaCl, 1 mM CaCl2 ; pH 7.0). The
mixture was incubated at 37‡C for 1 h and the reaction was stopped
by boiling for 5 min. The amount of the produced ETs was measured
in triplicate by sandwich enzyme immunoassay (EIA) as described
[22,26].
2.5. Analysis of puri¢ed ECE-3 by FPLC
The salt concentration of the active fraction from a HiTrap chelat-
ing column was reduced to approximately 1 mM by dilution with the
solubilizing bu¡er and subsequent ultra¢ltration with a Centriprep-30
concentrator. In this manner, 500 Wg of the resulting sample was
¢nally concentrated to approximately 1 ml. It was applied onto a
Resource Q column equilibrated with bu¡er B and eluted with a 25-
ml linear gradient of 0^1 M NaCl in bu¡er B at a £ow rate of 0.5 ml/
min on the FPLC instrument. 25-Wl aliquots from each 1-ml fraction
were assayed for ECE-3. Other 10-Wl aliquots were analyzed with
SDS-PAGE for estimation of the amount of the ECE-3 protein.
2.6. Measurement of the intracellular free calcium concentration
([Ca2+]i) in CHO-K1 cells transfected with cDNA for human
recombinant ETB receptor
Six microgram of puri¢ed ECE-3 was incubated at 37‡C for 2 h in
300 Wl of ECE reaction bu¡er in the presence of 0.5 WM big ET-3, and
the reaction was stopped by adding 3 Wl of 0.5 M EDTA. To remove
the detergent and other proteins from the product, 200 Wl of the
reaction mixture was loaded onto a Cosmosil 5C18-AR reverse phase
column (4.6 mmU250 mm) connected to HPLC (L-6200 intelligent
pump equipped with L-4250 UV-VIS detector; Hitachi, Japan) and
the peptides were eluted with a linear gradient of acetonitrile 0^20%
for 5 min, 20^35% for 10 min and 35^40% for 15 min in 0.1% tri-
£uoroacetic acid in 0.1% tri£uoroacetic acid at a £ow rate of 1.0 ml/
min. The eluate was monitored at A215 and 1-ml fractions were col-
lected. Under this condition, big ET-3 and ET-3 were eluted at re-
tention times of 21.2 and 23.5 min, respectively. The fraction corre-
sponding to the retention time of ET-3 was lyophilized and dissolved
in 10 Wl of 0.1% acetic acid for administration to CHO-K1 cells. The
absolute amount of ET-3 was assayed by sandwich EIA.
For measurement of [Ca2]i, CHO-K1 cells that stably expressed
human ETB receptors were incubated under reduced light with 5 WM
fura-2/AM in Ca2-free Krebs-HEPES solution (140 mM NaCl, 3 mM
KCl, 1 mM MgCl2, 10 mM HEPES, 1 mM glucose; pH 7.4) for
40 min at 37‡C as described [27^29]. After washing with Ca2-free
Krebs-HEPES solution, the cells were resuspended in Ca2-free
Krebs-HEPES solution at a density of approximately 2U107 cells/
ml, and 0.5-ml aliquots were used for measurement of £uorescence
with two excitation wavelengths at 340 nm and 380 nm and with an
emission wavelength at 500 nm by a CAF-110 intracellular ion ana-
lyzer (JASCO, Tokyo, Japan). CaCl2 (¢nal concentration: 2 mM) was
added to the cell suspension immediately before measurement of
[Ca2]i. The [Ca2]i was calculated from the ratio of £uorescence
intensities as described [30].
3. Results
3.1. Distribution of ECE in bovine eyeball
To examine the distribution of the converting activity in
bovine eyeballs, the eyeballs were divided into the retina, cho-
roid and iris, and ECE activities in these tissues were assayed
(Fig. 1). In the retina and choroid, the conversion activity of
big ET-1 to ET-1 was higher than that of big ET-3 to ET-3,
whereas both enzyme activities were comparable in the iris. In
addition, the conversion activity of big ET-3 was highest in
the iris. Therefore, we decided to use the iris for puri¢cation
of ECE-3.
3.2. Puri¢cation of bovine iris ECE-3
The data on puri¢cation are summarized in Table 1. The
supernatant after solubilization of microsomes was used as a
starting material.
Characteristically, the enzyme activity was increased after
incubation of the preparation with the blue B-agarose. That
is, the enzyme activity which was recovered in the supernatant
fraction of the blue B-agarose was increased to 270% of the
total activity in the starting material. When the enzyme activ-
ity remaining bound to blue B-agarose was eluted and as-
sayed, it was 130% of the activity in the starting material.
The recovered activity, amounting to 400% in total, suggests
that an inhibitor of the enzyme or a protease capable of in-
activating the enzyme was removed at this step. On the other
hand, the conversion activity of big ET-1 to ET-1 was un-
changed following the incubation with blue B-agarose: about
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Table 1











Supernatanta 69.4 28.3 0.41 100 1
Blue B-agarose (unbound fraction) 46.9 76.2 1.63 270 4.0
PNA agarose (pass-through fraction) 9.98 72 7.21 255 17.7
WGA agarose (eluate) 2.07 77.7 37.5 275 92.1
Hiload 26/60 superdex 200 pg 0.32 45.9 142 162 349
Zinc-chelating Sepharose (pass-through fraction) 0.2 53.2 266 188 653
aThis sample was prepared from bovine iris of 200 eyeballs.
This puri¢cation scheme was replicated four times. Data are from a typical experiment.
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half (52%) of the total activity in the starting material was
recovered in the supernatant fraction and the remaining half
was bound to the blue B-agarose (48%). Therefore, the super-
natant fraction was used for further puri¢cation of ECE-3.
The supernatant fraction was subsequently applied onto a
PNA agarose column and again the ECE-3 activity was re-
covered in the pass-through fraction with a 4.4-fold puri¢ca-
tion and 94% recovery. WGA agarose gave the best results
among the a⁄nity columns tested, providing a 5.2-fold puri-
¢cation. After gel ¢ltration by FPLC, ECE-3 activity was
reproducibly recovered in the fractions with retention times
of 130^142 min and a 3.8-fold puri¢cation was obtained. Fi-
nally, the fractions from FPLC were pooled and applied onto
a HiTrap chelating column: ECE-3 activity was recovered
with a 1.9-fold puri¢cation. The overall puri¢cation of ECE-
3 activity was approximately 653-fold from the starting mate-
rial with an apparent recovery of 188%. When the fractions
from each puri¢cation step were examined by SDS-PAGE
(Fig. 2), the enzyme was found to be puri¢ed to homogeneity
as a single band at 140 kDa after the HiTrap chelating col-
umn procedure. Furthermore, to con¢rm that the enzyme
activity is derived from the puri¢ed protein, anion-exchange
chromatography was performed. The elution pattern of the
enzyme activity in each fraction was found to be correlated
with that of the protein (Fig. 3).
3.3. Basic properties of ECE-3
The conversion of big ET-3 to ET-3 increased linearly with
time, but no plateau was reached within the observation time
(Fig. 4a). ECE-3 activity increased with the increases in big
ET-3 and reached a maximal activity of 3.5 pmol/min/mg
protein at concentrations higher than 2U1037 M. In contrast,
the conversion activity for big ET-1 was not detected up to a
concentration of 2U1036 M (Fig. 4b). Higher concentrations
of big ET-1 cannot be tested because of its solubility. Line-
weaver-Burk double reciprocal plots revealed that the Km and
Vmax values for big ET-3 were 0.14 WM and 7.4 pmol/min/mg
protein, respectively (Fig. 4c). The optimal pH was around 6.6
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Fig. 2. SDS-PAGE analysis of various fractions obtained during pu-
ri¢cation of ECE-3. Samples from each puri¢cation step were elec-
trophoresed on an SDS-polyacrylamide gel with a 4^20% gradient
of polyacrylamide and the protein was visualized with silver stain-
ing. Lane 1, molecular weight standards (100 ng of each protein);
myosin (200 kDa), L-galactosidase (116 kDa), phosphorylase b (97
kDa), serum albumin (66 kDa), ovalbumin (45 kDa). Lane 2, 10 Wg
of solubilized protein from iris microsomes with 0.1% lubrol PX.
Lane 3, 1 Wg of the fraction unbound to blue B-agarose. Lane 4,
1 Wg of the pass-through fraction from PNA agarose. Lane 5, 1 Wg
of the eluate from WGA agarose. Lane 6, 500 ng of pooled fraction
from Hiload 26/60 Superdex 200 pg. Lane 7, 500 ng of the pass-
through fraction from HiTrap chelating column. An arrow indicates
puri¢ed ECE.
Fig. 3. Analysis of puri¢ed ECE by FPLC. After concentration, the
puri¢ed ECE (the pass-through fraction from HiTrap chelating col-
umn) was applied onto the anion-exchange column (Resource Q)
connected with FPLC and eluted with a 25-ml linear gradient of 0^
1 M NaCl in bu¡er B at a £ow rate of 0.5 ml/min. A 25-Wl aliquot
from each 1-ml fraction was used for the assay of enzyme activity
(a) and the other for analysis by SDS-PAGE (b). The dashed line
indicates the concentration of NaCl in the elution bu¡er. An arrow
indicates the puri¢ed ECE.
Fig. 1. Distribution of the conversion activity of big ET-1 and big
ET-3 in various tissues of bovine eyeball. The eyeballs were divided
into the retina, choroid and iris. After homogenization of each tis-
sue, the solubilized microsomes were prepared and the conversion
activity of big ET-1 and big ET-3 in each preparation was assayed
as described in Section 2. For assays, the microsomal fractions con-
taining 1 mg of protein (bovine retina, choroid and iris) were incu-
bated in the presence of 0.5 WM big ET-1 or big ET-3 in ECE reac-
tion bu¡er for 1 h at 37‡C, respectively. The produced ET-1 (closed
column) and ET-3 (open column) were measured using sandwich
EIA.
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(Fig. 4d). The enzyme activity was inhibited by phosphorami-
don in a concentration-dependent manner, with an apparent
IC50 value of 0.05 WM, and complete inhibition was obtained
at 10 WM. In contrast, the enzyme activity was una¡ected by
thiorphan (Fig. 4e).
3.4. Measurement of [Ca2+]i in CHO-K1 cells transfected with
cDNA for human recombinant ETB receptor
To con¢rm that the product of the puri¢ed enzyme pos-
sesses the same biological activity as ET-3, we examined the
e¡ect of the product on [Ca2]i in CHO-K1 cells expressing
human ETB receptors. As shown in Fig. 5a, authentic 1039 M
ET-3 induced an increase in [Ca2]i in the CHO-K1 cells.
When the enzyme product isolated as described in Section 2
was added to the cells, it induced an increase in [Ca2]i. The
increase in [Ca2]i induced by the enzyme product containing
0.22 pmol (concentration: 0.44U1039 M) was comparable to
that by 1039 M ET-3. In contrast, no response was observed
when the sample was prepared from blank reaction mixtures
without either the puri¢ed enzyme or the substrate big ET-3,
or the reaction mixture without incubation (Fig. 5b). The
response of transfected CHO-K1 cells to the enzyme product
was abolished by 1036 M BQ788, a speci¢c antagonist for
ETB receptors (Fig. 5c), but not by 1036 M BQ123, a speci¢c
antagonist for ETA receptors (data not shown).
4. Discussion
In the present study, a novel enzyme which produces an
ET-3-like substance from big ET-3 was puri¢ed to apparent
homogeneity from bovine iris.
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Fig. 4. Basic properties of the puri¢ed ECE-3. (a) Time course of
ECE reaction. 3 Wg of the puri¢ed ECE was incubated with 0.5 WM
big ET-3 or 0.5 WM big ET-1 in 300 Wl of ECE reaction bu¡er at
37‡C for the indicated time, and the produced ET-3 (open square)
or ET-1 (closed circle) was measured. (b) E¡ect of substrate concen-
tration on the reaction rate. The assay of ECE activity was per-
formed in the same manner except that the reaction time was 60
min with the concentrations of big ET-3 being varied. Open
squares, big ET-3; closed circles, big ET-1. (c) Lineweaver-Burk
double reciprocal plots of data on ECE-3 activity in panel b. (d)
pH pro¢le of ECE-3 activity. The reaction was performed for 60
min in reaction mixture containing the indicated bu¡ers. That is, 50
mM MES bu¡er (square), 100 mM sodium phosphate bu¡er (trian-
gle) and 100 mM Tris bu¡er (circle) were used for the pH ranges of
5.5^6.8, 6.2^7.4 and 7.0^8.0, respectively. (e) E¡ect of phosphorami-
don and thiorphan on ECE-3 activity. The reaction was essentially
similar except that the reaction mixture contained the indicated con-
centrations of phosphoramidon (closed circle) or thiorphan (closed
square).
Fig. 5. E¡ect of the puri¢ed ECE-3 product on [Ca2]i in CHO-K1
cells expressing human ETB receptors. 6 Wg of the puri¢ed ECE (50
Wl) was incubated at 37‡C in 250 Wl of ECE reaction bu¡er in the
presence of 0.5 WM big ET-3 for 2 h (b and c; X) or 0 h (b; Y).
200 Wl of the reaction mixture was applied onto a Cosmosil 5C18-
AR reverse phase column and the peptides was eluted with a linear
gradient of acetonitrile. The fraction corresponding to the retention
time of ET-3 was collected, lyophilized and dissolved in 10 Wl of
0.1% acetic acid. 1 Wl of the solution was added to a 0.5-ml suspen-
sion of CHO-K1 cells expressing human ETB receptors in the ab-
sence (b) or presence (c; Z) of 1 WM BQ788 (an antagonist of ETB
receptor). (a) E¡ect of authentic 1039 M ET-3 on [Ca2]i. An arrow
indicates the addition of authentic ET-3 or the puri¢ed enzyme
products.
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This enzyme is characterized by a high selectivity for big
ET-3 over big ET-1 (Fig. 4), which distinguishes the puri¢ed
enzyme from ECE-1 or ECE-2 with a reverse order of selec-
tivity [14^17]. That is, the Km value of the puri¢ed enzyme for
big ET-3 is low (0.14 WM), whereas conversion of big ET-1 is
not detected up to 10 WM.
The product of this enzyme is identi¢ed as ET-3 itself or a
peptide with properties very close to ET-3 based on the fol-
lowing observations. The enzyme product has (1) the same
immunoreactivity as ET-3, (2) the same retention time as
ET-3 on HPLC with a reverse phase column, and (3) the
same biological activity as ET-3, in that it can raise [Ca2]i
in the cells expressing ETB receptors with a potency compa-
rable to that of authentic ET-3 (Fig. 5). Taken together, these
results show that the puri¢ed enzyme is a new member of the
ECE family, namely ECE-3.
Furthermore, the molecular mass of the puri¢ed enzyme
appears to be about 140 kDa (Fig. 2), which is slightly larger
than those of ECE-1 and ECE-2 (130 kDa) [13,14].
This enzyme seems to be a metalloprotease like other mem-
bers of the ECE family such as ECE-1 and ECE-2, based on
the data that the activity of the puri¢ed enzyme is blocked by
phosphoramidon but not by thiorphan.
The extent of puri¢cation appears to be not so high as that
of ECE-1 [31]. This seems to be mainly due to co-localization
of other types of ECE like ECE-1 or ECE-2 in bovine iris
which can convert big ET-3 to ET-3 as previously described
[14,17]. Therefore, the actual fold puri¢cation could be higher,
unless the starting material did not contain ECE-1 activity.
We are trying to microsequence the puri¢ed enzyme and
isolate cDNA for ECE-3.
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